Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration
Biomolecules · 20.03.2026 · 16 (3) · 467
DOI: 10.3390/biom16030467 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 20.03.2026. Verfasst von Dhienda C Shahannaz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Induced Pluripotent Stem Cells, Regeneration, Extracellular Vesicles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular disease remains the leading global cause of mortality, largely due to the limited regenerative capacity of adult human myocardium. Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) offer a scalable platform for cardiac repair and disease modeling; however, their persistent metabolic immaturity—characterized by reliance on glycolysis, reduced oxidative phosphorylation (OXPHOS), and structurally underdeveloped mitochondria—limits functional integration and long-term therapeutic efficacy. Recent advances indicate that targeted metabolic reprogramming can enhance mitochondrial biogenesis, increase ATP production, and improve stress resilience in iPSC-CMs. This review examines the complementary integration of CRISPR-based metabolic engineering and extracellular vesicle (EV)-mediated metabolic modulation as a systems-level strategy for cardiac maturation. We discuss CRISPR activation, interference, and epigenome-editing approaches targeting regulators such as PGC-1α, TFAM, and PPARs to promote stable enhancement of mitochondrial networks and respiratory capacity. In parallel, engineered EVs delivering miRNAs, metabolic enzymes, and redox modulators provide non-genomic mechanisms to optimize bioenergetic function and mitigate oxidative stress. By synthesizing mechanistic insights, quantitative bioenergetic metrics, and translational considerations, we propose CRISPR-EV synergy as a precision framework for durable metabolic maturation of iPSC-CMs, with implications for regenerative therapy, pharmacologic screening, and myocardial repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
ORCID-Profile: Dhienda C Shahannaz, Tadahisa Sugiura
Zitieren
APA
Shahannaz, D. C., & Sugiura, T. (2026). Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration. Biomolecules, 16(3), 467. https://doi.org/10.3390/biom16030467
Vancouver
Shahannaz DC, Sugiura T. Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration. Biomolecules. 2026;16(3):467. doi:10.3390/biom16030467
BibTeX
@article{Shahannaz2026,
author = {Shahannaz, Dhienda C and Sugiura, Tadahisa},
title = {Next-Generation Metabolic Reprogramming in iPSC-Derived Cardiomyocytes: CRISPR-EV Synergy for Precision Cardiac Regeneration},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {3},
pages = {467},
doi = {10.3390/biom16030467}
}
EUVIMED